Blood Cancer-MKGIMI BIOTECH

NCT06435910 Engineered Dendritic Cell Vaccines for Remission Maintenance in MultipleMyeloma Patients'

Estimated Enrollment:

10

NCT06429150 Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma WithBCMA and GPRC5D Combination CAR-T Cell Therapy'

Estimated Enrollment:

20

NCT05995041 Universal CAR-T Cells Targeting AML'

Estimated Enrollment:

30

NCT06006741 Universal CAR-T Cells Targeting Multiple Myeloma'

Estimated Enrollment:

20

NCT05995028 Universal 4SCAR7U Targeting CD7-positive Malignancies'

Estimated Enrollment:

30

NCT05995015 4SCAR19U T Cells Targeting B Cell Malignancies'

Estimated Enrollment:

30

NCT05436509 CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies'

Estimated Enrollment:

60

NCT05436496 CD19/70 Bi-specific CAR-T Cells Targeting B Cell Malignancies'

Estimated Enrollment:

30

NCT05432882 CD19/22 Bi-specific CAR-T Cells Targeting B Cell Malignancies'

Estimated Enrollment:

60

NCT05277753 NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL'

Estimated Enrollment:

10

NCT05262673 NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL'

Estimated Enrollment:

10

NCT04637503 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma'

Estimated Enrollment:

100

NCT04430530 4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia'

Estimated Enrollment:

100

NCT04429438 Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas'

Estimated Enrollment:

11

NCT04427449 Multi-center Phase I/II Clinical Trial of 4SCAR-CD44v6 T Cells for Treating Cancer'

Estimated Enrollment:

100

NCT04033302 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies'

Estimated Enrollment:

30

NCT04010877 Multi-center Phase I/II Clinical Trial of Multiple CAR T Cells for Treating Acute Myeloid Leukemia'

Estimated Enrollment:

10

NCT04016129 CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia'

Estimated Enrollment:

100

NCT03222674 Multi-center Phase I/II Clinical Trial of Multi-CART Cell Therapy for Acute Myeloid Leukemia'

Estimated Enrollment:

10

NCT03271632 Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma'

Estimated Enrollment:

20

NCT03125577 Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20,20,38, and 123 Targeting Hematological Malignancies'

Estimated Enrollment:

200

NCT03050190 A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies'

Estimated Enrollment:

200